VRTX · News · 20260811N
Acquisition / Partnership / Divestiture
VERTEX PHARMACEUTICALS INC / MA · 2026-08-11 · Importance 71 · Surprise 60 · In source text
Vertex agreed to acquire Crinetics Pharmaceuticals for US$85 per share in cash, implying a transaction value of approximately US$10 billion. The deal is expected to close in the third quarter of 2026, subject to customary conditions. The acquisition would expand Vertex’s portfolio beyond cystic fibrosis and support its broader pipeline diversification strategy.
Key facts
- Vertex Pharmaceuticals agreed to acquire Crinetics for $85 per share in cash in a deal valued at approximately $10 billion, expected to close in Q3 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -31.0% | Vertex Pharmaceuticals agreed to acquire Crinetics for $85 per share in cash in a deal valued at approximately $10 billion, expected to… |
| assets | positive | committed | +31.0% | Vertex Pharmaceuticals agreed to acquire Crinetics for $85 per share in cash in a deal valued at approximately $10 billion, expected to… |